Testing IMM-H014 for metabolic liver disease
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have fatty liver disease (steatosis) and at least one other health condition like high blood pressure, diabetes, or high cholesterol.
- Your liver enzyme (ALT) is higher than normal, or you've had a liver biopsy showing MASH scarring recently.
- You have at least 10% liver fat as measured by a special MRI scan.
- You are willing to keep your usual diet and exercise habits during the study.
- You are not a heavy drinker, have no other serious liver diseases, and are not taking certain medications that affect the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests a new drug called IMM-H014 in healthy volunteers to see if it is safe and how the body processes it. It also checks if food changes how the drug works. You may join if you are generally healthy and meet the age and weight requirements.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This trial tests a new drug called TGM-312-SC01 to see if it can help people with MASH (a type of fatty liver disease that causes inflammation and damage). It is for adults aged 18 to 70 who are otherwise healthy or have MASH.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.